KYMR

Kymera Therapeutics, Inc.

• Reuters·04/01 23:00

  Kymera COO Jeremy G Chadwick disposes of USD 1.9 million common shares

• Reuters·04/01 23:00

  Kymera director Elena Ridloff disposes of USD 1.3 million common shares

• Benzinga·03/31 13:57

  Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

• Benzinga·03/30 07:16

  Reported Saturday, Kymera's Phase 1b BroADen Data Shows KT-621 Delivers Robust Type 2 Inflammatory Biomarker Reductions And Meaningful Clinical Improvements In Moderate-To-Severe Atopic Dermatitis

• TipRanks·03/29 14:31

  Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621

• Reuters·03/28 15:00

  Kymera says oral STAT6 degrader KT-621 shows positive Phase 1b atopic dermatitis data

• TipRanks·03/27 21:49

  Kymera Therapeutics Updates Bylaws on Federal Securities Litigation

• Reuters·03/27 20:31

  Kymera Therapeutics amends bylaws; federal district courts named exclusive forum for Securities Act and Exchange Act claims

• Reuters·03/25 21:15

  Kymera Therapeutics; COO Jeremy G Chadwick disposes of common shares worth $9,033,226

• Reuters·03/20 22:30

  Kymera Therapeutics director Pamela Esposito disposes of USD 198,920 in common shares

• Seeking Alpha·03/19 18:37

  Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech

• Seeking Alpha·03/18 00:54

  Tracking Baker Brothers Portfolio - Q4 2025 Update

• Dow Jones·03/16 18:41

  Kymera Therapeutics Price Target Cut to $110.00/Share From $122.00 by Jefferies

• TipRanks·03/16 13:39

  Kymera Therapeutics assumed with a Buy at Jefferies

• TipRanks·03/16 13:35

  Kymera Therapeutics (KYMR) Initiated with a Buy at Jefferies